chemieunternehmen.com

Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. („Censo“) to source and provide patient-derived induced pluripotent stem cells („iPSC“) to support Evotec’s broad iPSC platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-ipsc-drug-discovery-leadership-through-strategic-collaboration-with-censo-biotechnologies-5474

Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab282-accelerates-with-second-round-funding-5472

Evotec AG announced today that it will make a strategic investment as part of Facio Therapies‘ („Facio“) 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy („FSHD“) community (Total volume: EUR 4.8 m). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-strategic-investment-in-facio-therapies-to-support-development-of-novel-fshd-therapy-5470

Evotec AG was awarded the European Mediscience Award for “Company of the Year”.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-european-mediscience-award-for-company-of-the-year-5467

Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney diseasefocused drug discovery based on patient derived-data. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-nurture-consortium-to-mine-unique-kidney-disease-patient-biobank-5464

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting, which took place today, with the required majority. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/resolutions-of-the-annual-general-meeting-2017-of-evotec-ag-5466

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at  ASM MICROBE 2017 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forge-therapeutics-and-evotec-present-first-efficacy-data-for-lpxc-inhibitor-in-uti-model-at–asm-microbe-2017-5461

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-endometriosis-alliance-with-bayer-5460

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-attend-three-upcoming-investor-conferences-5458